Neumora Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 30, 2026, 4:05 p.m. ETView on SEC.gov Our explainer
Delisting notice / failure to meet listing standard
AI summary, unreviewedNeumora Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice, Has Until April 26, 2027 to Regain Compliance
4Aug. 21, 2026, 7:10 p.m. ETView on SEC.gov
4Aug. 21, 2026, 7:10 p.m. ETView on SEC.gov
4Aug. 21, 2026, 7:08 p.m. ETView on SEC.gov
4Aug. 21, 2026, 7:08 p.m. ETView on SEC.gov
4Aug. 21, 2026, 7:06 p.m. ETView on SEC.gov
4Aug. 19, 2026, 7:17 p.m. ETView on SEC.gov
10-QAug. 14, 2026, 7:23 a.m. ETView on SEC.gov
8-KAug. 14, 2026, 7:13 a.m. ETView on SEC.gov
Results of operations and financial condition · Departure/appointment of directors or officers · Financial statements and exhibits
8-KJuly 27, 2026, 7:07 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits